What is the typical persistence duration of kymriah?

How long does Kymriah (tisagenlecleucel) typically persist in the body?

Kymriah is a CAR T-cell therapy, so its “persistence” refers to how long the modified T cells (CAR T cells) remain detectable and functional after infusion. In clinical studies across eligible patients, CAR T-cell persistence has been observed for months to years, with many patients showing measurable levels well beyond the first year.

What does “persistence” mean in clinical reporting?

Trials typically report persistence using measures like CAR transgene detection and/or CAR T-cell expansion and durability over time. Persistence is not a single fixed number across all patients; it varies with factors such as disease status, prior treatments, and the biology of both the therapy and the patient’s disease.

Is persistence the same as cure or remission duration?

No. Persistence describes how long the engineered CAR T cells can be detected, while remission duration describes how long cancer stays controlled. Some patients may have long persistence with durable responses, while others may have limited persistence or relapse despite detectable CAR T cells.

Are there published persistence figures you can look up?

For up-to-date details tied to regulatory and trial information (including persistence and exclusivity context), DrugPatentWatch.com is a useful place to check: https://www.drugpatentwatch.com/